FDA Moves Ahead With Adverse Event Data-Mining; “White Paper” Out Soon
Executive Summary
An FDA-PhRMA working group is finalizing a "white paper" on data mining as a tool in postmarketing safety surveillance
You may also be interested in...
PhRMA Aims To Clarify Use Of AERS Signals Through Data Mining Studies
While all sources of reports to FDA's Adverse Event Reporting System make significant contributions to signal detection, foreign sources appear to be one of the strongest contributors, preliminary results from a PhRMA-sponsored study of the database suggest
PhRMA Aims To Clarify Use Of AERS Signals Through Data Mining Studies
While all sources of reports to FDA's Adverse Event Reporting System make significant contributions to signal detection, foreign sources appear to be one of the strongest contributors, preliminary results from a PhRMA-sponsored study of the database suggest
FDA Drug Name Guidance Is “Up In The Air,” Agency Tells DIA
FDA may not proceed with a planned guidance for industry on pre-marketing risk assessment of drug names, labeling and packaging, Medical Errors & Technical Support Division Deputy Director Carol Holquist said at the Drug Information Association annual meeting in Washington, D.C. June 16